98%
921
2 minutes
20
Background: We aimed to explore the relationship between preoperative patient-reported outcome measure (PROMs) phenotypes based on pain, function, and mental health with postoperative achievement of minimal clinically important difference (MCID), patient acceptable symptom state (PASS) thresholds, and satisfaction at one year in patients undergoing medial unicompartmental knee arthroplasty (mUKA).
Methods: A prospective institutional cohort of 941 patients undergoing mUKA from 2016 to 2022 was included. Of these, 143 underwent robotic-assisted (RA)-mUKA and 798 underwent manual mUKA. Preoperative scores on Knee disability and Osteoarthritis Outcome Score for Pain (KOOS Pain), KOOS Physical Function Shortform (KOOS PS), and the Veterans RAND 12-Item Health Survey Mental Component Score (MCS) were used to develop eight distinct PROM phenotypes representing above (+) or below (-) the median score for the cohort.
Results: Select preoperative PROM phenotypes were associated with a lower likelihood of failure to achieve MCID for KOOS PS and JR, while they were more likely to fail to achieve PASS thresholds for all KOOS domains.
Conclusion: Patients undergoing mUKA who have certain baseline PROM phenotypes may not reach an acceptable symptomatic state, despite experiencing meaningful improvements at one year. These phenotypes could help determine surgical timing and identify high-risk patients who may benefit from targeted preoperative interventions and expectation management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arth.2025.08.043 | DOI Listing |
Int J Gynaecol Obstet
September 2025
Department of Gynecology and Obstetrics, Justus Liebig University Giessen, Giessen, Germany.
Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-releasing hormone (GnRH) antagonists have been approved for this indication.
View Article and Find Full Text PDFHead Neck
September 2025
Department of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, Canada.
Background: Salvage surgery (SS) is one of the best treatment options for recurrent oropharyngeal squamous cell carcinoma (OPSCC) after prior definitive radiation.
Methods: A Medline literature search of articles on open (OSS) and transoral robotic surgery (TORS) for the treatment of recurrent OPSCC was performed. Surgical, functional, and oncological outcomes were analyzed and compared.
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.
Curr Med Imaging
September 2025
Department of Pharmacy, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Unlabelled: Leptomeningeal metastasis (LM) is a severe complication of solid malignancies, including lung adenocarcinoma, characterized by poor prognosis and diagnostic challenges. This study assesses whether curvilinear peri-brainstem hyperintense signals on MRI are a characteristic feature of LM in lung adenocarcinoma patients.
Methods: This retrospective study analyzed data from multiple centers, encompassing lung adenocarcinoma patients with peri-brainstem curvilinear hyperintense signals on MRI between January 2016 and March 2022.
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.